← All drugs
Drug · FAERS side-effect profile with label screen

Metformin side effects: what 354,745 FDA adverse event reports show

Metformin · Metformin Hydrochloride · 1,153 reaction terms · 1,303,421 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Metformin Hydrochloride

openFDA label

Who reports

354,745 reports · 69% serious · 29,950 with death outcome · 54% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 )

FDA label, Indications and Usage

What it is

Metformin is a member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1. It has a role as a geroprotector, a hypoglycemic agent, a xenobiotic and an environmental contaminant.

PubChem CID 4091 (ChEBI)

Boxed warning

LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 3Labeled adverse reaction 3Labeled (related wording) 5Likely indication confounding 2Reporting / coding artifact 2Lab value / disease marker 9Not in label — unassessed 16
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,113 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Lactic acidosis17,14167.6
66.2–69.1ROR 71.0 · calibrated p 1e-6 ✓
31.6 EB05 31.2 · IC025 +5.0
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 53.5 · serious PRR 26.4 · 96% clinicianno trial arm names this drug
Neurologic neglect syndrome28962.7
53.1–74.1ROR 62.8 · calibrated p 4e-6 ✓
30.4 EB05 27.6 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=289 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Pulmonary vasculitis22643.8
36.8–52.0ROR 43.8 · calibrated p 3e-5 ✓
25.2 EB05 22.6 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=226 · ♀ 0% (drug 54%) · 100% clinicianno trial arm names this drug
Carotid artery thrombosis29631.0
26.9–35.7ROR 31.0 · calibrated p 2e-4 ✓
20.5 EB05 18.6 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=296 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Hyperlactacidaemia80425.6
23.6–27.8ROR 25.7 · calibrated p 6e-4 ✓
18.0 EB05 17.0 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=804 · 100% clinicianno trial arm names this drug
Adjustment disorder30117.5
15.4–19.9ROR 17.5 · calibrated p 0.004 ✓
13.6 EB05 12.4 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=299 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Metabolic acidosis6,20014.2
13.8–14.6ROR 14.4 · calibrated p 0.008 ✓
11.6 EB05 11.3 · IC025 +3.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 13.0 · serious PRR 9.7 · 94% clinicianno trial arm names this drug
Glycosylated haemoglobin increased4,53912.8
12.4–13.2ROR 13.0 · calibrated p 0.013 ✓
10.6 EB05 10.4 · IC025 +3.4
3/3 methods agree
Lab value / disease markerserious PRR 9.6no trial arm names this drug
Ketoacidosis1,34712.8
12.1–13.6ROR 12.8 · calibrated p 0.013 ✓
10.6 EB05 10.2 · IC025 +3.3
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 8.9no trial arm names this drug
Glycosylated haemoglobin abnormal21012.6
10.8–14.6ROR 12.6 · calibrated p 0.015 ✓
10.4 EB05 9.3 · IC025 +3.1
3/3 methods agree
Lab value / disease marker♀ 0% (drug 54%) · 100% consumerno trial arm names this drug
Hypoglycaemic coma50812.4
11.3–13.7ROR 12.4 · calibrated p 0.015 ✓
10.3 EB05 9.6 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=508 · 100% clinicianno trial arm names this drug
Gastrointestinal hypomotility38412.1
10.8–13.5ROR 12.1 · calibrated p 0.016 ✓
10.1 EB05 9.3 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=380 · 100% consumerno trial arm names this drug
Diabetic ketoacidosis4,05311.9
11.5–12.3ROR 12.0 · calibrated p 0.017 ✓
10.0 EB05 9.7 · IC025 +3.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 13.2 · serious PRR 8.4no trial arm names this drug
Glycosylated haemoglobin decreased24310.5
9.1–12.0ROR 10.5 · calibrated p 0.028 ✓
8.9 EB05 8.0 · IC025 +2.9
3/3 methods agree
Lab value / disease marker100% consumerno trial arm names this drug
Hypoglycaemia (low blood sugar)7,28710.3
10.0–10.5ROR 10.5 · calibrated p 0.027 ✓
8.9 EB05 8.7 · IC025 +3.1
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 8.7 · serious PRR 7.8no trial arm names this drug
Neuritis22710.1
8.7–11.6ROR 10.1 · calibrated p 0.032 ✓
8.6 EB05 7.7 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=225 · ♀ 0% (drug 54%) · 100% clinicianno trial arm names this drug
Blood lactic acid increased7249.3
8.6–10.1ROR 9.3 · calibrated p 0.041 ✓
8.1 EB05 7.6 · IC025 +2.9
3/3 methods agree
Lab value / disease markerserious n=703 · 100% clinicianno trial arm names this drug
Distributive shock3059.3
8.3–10.5ROR 9.3 · calibrated p 0.041 ✓
8.1 EB05 7.3 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=305 · 100% clinicianno trial arm names this drug
Impaired gastric emptying1,7519.3
8.8–9.7ROR 9.3 · calibrated p 0.041 ✓
8.1 EB05 7.8 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious PRR 7.3 · 87% consumerno trial arm names this drug
Diabetic neuropathy6709.0
8.3–9.8ROR 9.1 · calibrated p 0.045 ✓
7.9 EB05 7.4 · IC025 +2.9
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=572no trial arm names this drug
Personality disorder3458.8
7.8–9.8ROR 8.8 · calibrated p 0.051
7.7 EB05 7.0 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=341 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Blood bicarbonate decreased2458.6
7.5–9.8ROR 8.6 · calibrated p 0.055
7.5 EB05 6.7 · IC025 +2.7
3/3 methods agree
Lab value / disease markerserious n=244 · ♀ 0% (drug 54%) · 100% clinicianno trial arm names this drug
Suspected suicide5788.0
7.4–8.8ROR 8.0 · calibrated p 0.066
7.1 EB05 6.7 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=578 · 100% clinicianno trial arm names this drug
Hyperparathyroidism secondary2957.7
6.8–8.7ROR 7.7 · calibrated p 0.076
6.8 EB05 6.2 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=295no trial arm names this drug
Blood pressure diastolic abnormal2987.6
6.8–8.6ROR 7.6 · calibrated p 0.078
6.8 EB05 6.2 · IC025 +2.6
3/3 methods agree
Lab value / disease markerserious n=295 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Nephrogenic anaemia5367.5
6.9–8.2ROR 7.5 · calibrated p 0.080
6.7 EB05 6.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=536no trial arm names this drug
Diabetic retinopathy3897.5
6.8–8.4ROR 7.5 · calibrated p 0.081
6.7 EB05 6.2 · IC025 +2.6
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=358no trial arm names this drug
Blood glucose fluctuation1,2487.5
7.0–7.9ROR 7.5 · calibrated p 0.082
6.7 EB05 6.4 · IC025 +2.6
3/3 methods agree
Lab value / disease markerserious n=697no trial arm names this drug
Acute kidney injury (sudden kidney damage)17,2317.4
7.3–7.5ROR 7.7 · calibrated p 0.073
6.7 EB05 6.6 · IC025 +2.7
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 6.0 · serious PRR 5.6no trial arm names this drug
Hyperkalaemia (high potassium)3,9247.4
7.1–7.6ROR 7.4 · calibrated p 0.083
6.6 EB05 6.5 · IC025 +2.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 5.6 · serious PRR 5.7 · 93% clinicianno trial arm names this drug
Blood glucose abnormal2,0607.3
7.0–7.6ROR 7.3 · calibrated p 0.087
6.6 EB05 6.3 · IC025 +2.6
3/3 methods agree
Lab value / disease markerserious PRR 6.4no trial arm names this drug
Insulin resistance2287.3
6.3–8.4ROR 7.3 · calibrated p 0.089
6.5 EB05 5.8 · IC025 +2.5
3/3 methods agree
Reporting / coding artifact♀ 100% (drug 54%) · 100% consumerno trial arm names this drug
Forced expiratory volume decreased2946.7
6.0–7.6ROR 6.7 · calibrated p 0.111
6.1 EB05 5.5 · IC025 +2.4
3/3 methods agree
Lab value / disease markerserious n=294 · ♀ 0% (drug 54%)no trial arm names this drug
Pancreatic carcinoma metastatic2876.5
5.7–7.3ROR 6.5 · calibrated p 0.123
5.9 EB05 5.3 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious n=287 · 100% clinicianno trial arm names this drug
Drug level above therapeutic4526.4
5.8–7.1ROR 6.4 · calibrated p 0.126
5.8 EB05 5.4 · IC025 +2.4
3/3 methods agree
Reporting / coding artifactserious n=452 · 100% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Hypoglycaemia11,6238.07.9–8.2signal
Hyperglycaemia / diabetes32,2676.05.9–6.0signal
Kidney injury28,6563.93.8–3.9signal
Pancreatitis4,5973.53.4–3.6signal
Hyponatraemia2,9202.22.1–2.3signal
Rhabdomyolysis / myopathy2,8772.12.1–2.2signal
Arrhythmia / qt5,6651.81.7–1.8raised
Gi bleeding5,2881.71.7–1.8raised
Heart failure4,8441.61.6–1.7raised
Fall / fracture10,2401.61.6–1.6raised
Suicidality6,3521.51.5–1.6raised
Myocardial infarction5,2521.51.5–1.6raised
Anaemia7,5231.51.5–1.5raised
Serious infection18,6321.41.4–1.5raised
Stroke5,8321.41.4–1.4raised
Liver injury6,7781.31.3–1.4raised

Trial evidence (ClinicalTrials.gov)

No completed trial with posted adverse-event results was found on ClinicalTrials.gov for Metformin (searched METFORMIN).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Diarrhoea (diarrhea)22,9692.2
2.1–2.2ROR 2.2 · calibrated p 0.936
2.1 EB05 2.1 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 2.0no trial arm names this drug
Nausea22,9451.7
1.7–1.8ROR 1.8 · calibrated p 0.825
1.7 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.7no trial arm names this drug
Drug ineffective (drug did not work)18,9510.8
0.8–0.9ROR 0.8 · calibrated p 0.207
0.9 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 1.0 · serious PRR 1.0no trial arm names this drug
Blood glucose increased18,6316.4
6.3–6.4ROR 6.7 · calibrated p 0.114
5.8 EB05 5.7 · IC025 +2.5
3/3 methods agree
Lab value / disease markerage-adj. PRR 4.8 · serious PRR 5.1 · 78% consumerno trial arm names this drug
Fatigue (tiredness)17,9261.4
1.4–1.4ROR 1.4 · calibrated p 0.570
1.4 EB05 1.3 · IC025 +0.4Not in label — unassessedage-adj. PRR 1.2 · serious PRR 1.4no trial arm names this drug
Acute kidney injury (sudden kidney damage)17,2317.4
7.3–7.5ROR 7.7 · calibrated p 0.073
6.7 EB05 6.6 · IC025 +2.7
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 6.0 · serious PRR 5.6no trial arm names this drug
Lactic acidosis17,14167.6
66.2–69.1ROR 71.0 · calibrated p 1e-6 ✓
31.6 EB05 31.2 · IC025 +5.0
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 53.5 · serious PRR 26.4 · 96% clinicianno trial arm names this drug
Vomiting15,5552.0
2.0–2.0ROR 2.0 · calibrated p 0.966
2.0 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 2.0 · serious PRR 1.9no trial arm names this drug
Off label use (used outside approved label)14,1241.0
0.9–1.0ROR 1.0 · calibrated p 0.280
1.0 EB05 0.9 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 1.1no trial arm names this drug
Dyspnoea (shortness of breath)14,0411.5
1.5–1.5ROR 1.5 · calibrated p 0.641
1.5 EB05 1.4 · IC025 +0.5Not in label — unassessedage-adj. PRR 1.3 · serious PRR 1.4no trial arm names this drug
Dizziness12,6381.5
1.5–1.5ROR 1.5 · calibrated p 0.663
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.5no trial arm names this drug
Headache12,4591.2
1.2–1.2ROR 1.2 · calibrated p 0.430
1.2 EB05 1.2 · IC025 +0.2Labeled adverse reaction
exact term
age-adj. PRR 1.1 · serious PRR 1.3no trial arm names this drug
Weight decreased (weight loss)12,3172.7
2.6–2.7ROR 2.7 · calibrated p 0.715
2.6 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.2 · serious PRR 2.1no trial arm names this drug
Pain12,0511.2
1.1–1.2ROR 1.2 · calibrated p 0.417
1.2 EB05 1.1 · IC025 +0.2Labeled — boxed warning
exact term
age-adj. PRR 1.3 · serious PRR 1.1no trial arm names this drug
Asthenia (weakness)10,8781.7
1.7–1.8ROR 1.8 · calibrated p 0.802
1.7 EB05 1.7 · IC025 +0.7Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.6no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Metformin ↔ Lactic acidosis.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Metformin?

In FDA FAERS, the most frequently co-reported reaction terms for Metformin are diarrhoea, nausea, blood glucose increased, fatigue, acute kidney injury, lactic acidosis. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Metformin have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.

Do FAERS signals prove that Metformin causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.